WBAG:QGEN

Stock Analysis Report

Executive Summary

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide.

Snowflake

Fundamentals

Proven track record with moderate growth potential.


Similar Companies

Share Price & News

How has QIAGEN's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.5%

WBAG:QGEN

2.1%

AT Life Sciences

1.4%

AT Market


1 Year Return

-8.2%

WBAG:QGEN

5.2%

AT Life Sciences

-6.1%

AT Market

QGEN underperformed the Life Sciences industry which returned 5.2% over the past year.

QGEN underperformed the Market in Austria which returned -5.1% over the past year.


Share holder returns

QGENIndustryMarket
7 Day-0.5%2.1%1.4%
30 Day-13.2%-3.8%-2.6%
90 Day-10.3%3.8%0.7%
1 Year-8.2%-8.2%6.1%5.2%-2.6%-6.1%
3 Yearn/a75.4%66.3%49.5%35.7%
5 Yearn/a224.9%200.3%52.2%30.3%

Price Volatility Vs. Market

How volatile is QIAGEN's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is QIAGEN undervalued based on future cash flows and its price relative to the stock market?

5%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

QIAGEN's share price is below the future cash flow value, but not at a moderate discount (< 20%).

QIAGEN's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

QIAGEN is overvalued based on earnings compared to the Europe Life Sciences industry average.

QIAGEN is overvalued based on earnings compared to the Austria market.


Price Based on Expected Growth

QIAGEN is poor value based on expected growth next year.


Price Based on Value of Assets

QIAGEN is overvalued based on assets compared to the Europe Life Sciences industry average.


Next Steps

Future Growth

How is QIAGEN expected to perform in the next 1 to 3 years based on estimates from 18 analysts?

18.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

QIAGEN's revenue is expected to grow by 8.1% yearly, however this is not considered high growth (20% yearly).

QIAGEN's earnings are expected to grow by 18.9% yearly, however this is not considered high growth (20% yearly).

QIAGEN's revenue growth is expected to exceed the Austria market average.

QIAGEN's earnings growth is expected to exceed the Austria market average.

QIAGEN's earnings growth is expected to exceed the low risk savings rate of 0.5%.


Earnings per Share Growth Estimates


Future Return on Equity

QIAGEN is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has QIAGEN performed over the past 5 years?

0.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

QIAGEN's year on year earnings growth rate has been positive over the past 5 years.

QIAGEN's 1-year earnings growth exceeds its 5-year average (151% vs 0.6%)

QIAGEN's earnings growth has exceeded the Europe Life Sciences industry average in the past year (151% vs 10.3%).


Return on Equity

QIAGEN has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

QIAGEN used its assets less efficiently than the Europe Life Sciences industry average last year based on Return on Assets.


Return on Capital Employed

QIAGEN has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is QIAGEN's financial position?


Financial Position Analysis

QIAGEN is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

QIAGEN's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

QIAGEN's level of debt (67.5%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (42.6% vs 67.5% today).

Debt is not well covered by operating cash flow (18%, less than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 5.3x coverage).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.9x debt.


Next Steps

Dividend

What is QIAGEN's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate QIAGEN's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate QIAGEN's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as QIAGEN has not reported any payouts.

Unable to verify if QIAGEN's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as QIAGEN has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of QIAGEN's dividends in 3 years as they are not expected to pay a notable one for Austria.


Next Steps

Management

What is the CEO of QIAGEN's salary, the management and board of directors tenure and is there insider trading?

4.4yrs

Average management tenure


CEO

Peer Schatz (53yo)

15.6yrs

Tenure

US$2,025,315

Compensation

Mr. Peer Michael Schatz serves as Managing Director of QIAGEN Hannover GmbH. Mr. Schatz has been the Chief Executive Officer and Managing Director of Qiagen NV since January 1, 2004. He serves as Chief Exe ...


CEO Compensation Analysis

Insufficient data for Peer to establish whether their remuneration is reasonable compared to companies of similar size in .

Peer's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

4.4yrs

Average Tenure

52yo

Average Age

The tenure for the QIAGEN management team is about average.


Board Age and Tenure

6.2yrs

Average Tenure

61yo

Average Age

The tenure for the QIAGEN board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$169,13607 Mar 19
Lawrence Rosen
EntityIndividual
Role
Member of Supervisory Board
Supervisory Director
Shares4,886
Max PriceUS$34.62

Ownership Breakdown


Management Team

  • Peer Schatz (53yo)

    CEO, MD & Member of Management Board

    • Tenure: 15.6yrs
    • Compensation: US$2.03m
  • Roland Sackers (50yo)

    CFO, MD & Member of Management Board

    • Tenure: 15.6yrs
    • Compensation: US$889.00k
  • Thomas Schweins

    Senior Vice President of Life Science Business Area

    • Tenure: 1.6yrs
  • Thierry Bernard

    Senior Vice President of Molecular Diagnostics Business Area

    • Tenure: 4.5yrs
  • John Gilardi

    Vice President of Corporate Communications & Investor Relations

    • Tenure: 8.8yrs
  • Jonathan Sheldon

    Senior Vice President of Bioinformatics Business Area

    • Tenure: 1.6yrs
  • Manuel Méndez (51yo)

    Senior Vice President of Global Commercial Operations

    • Tenure: 4.8yrs
  • Jean-Pascal Viola

    Head of Corporate Business Development

    • Tenure: 4.3yrs
  • Barthold Piening (61yo)

    Senior VP & Head of Global Operations

    • Tenure: 0.7yrs
  • Annette Koch

    Senior VP & Chief Human Resources Officer

    • Tenure: 1.6yrs

Board Members

  • Metin Colpan (64yo)

    Supervisory Director

    • Tenure: 15.6yrs
    • Compensation: US$75.50k
  • Liz Tallett (70yo)

    Supervisory Director

    • Tenure: 8.2yrs
    • Compensation: US$96.50k
  • Sven Björklund (63yo)

    Supervisory Board Chairman

    • Tenure: 1.2yrs
    • Compensation: US$123.75k
  • Larry Rosen (61yo)

    Supervisory Director

    • Tenure: 6.2yrs
    • Compensation: US$82.50k
  • Elaine Mardis (56yo)

    Supervisory Director

    • Tenure: 5.2yrs
    • Compensation: US$63.50k
  • Stéphane Bancel (46yo)

    Supervisory Director

    • Tenure: 6.2yrs
    • Compensation: US$89.50k
  • Ross Levine (47yo)

    Supervisory Director

    • Tenure: 3.6yrs
    • Compensation: US$63.50k

Company Information

QIAGEN N.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: QIAGEN N.V.
  • Ticker: QGEN
  • Exchange: WBAG
  • Founded: 1986
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$7.768b
  • Listing Market Cap: US$6.973b
  • Shares outstanding: 226.47m
  • Website: https://www.qiagen.com

Number of Employees


Location

  • QIAGEN N.V.
  • Hulsterweg 82
  • Venlo
  • Limburg
  • 5912 PL
  • Netherlands

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QGENNYSE (New York Stock Exchange)YesCommon SharesUSUSDJun 1996
QIADB (Deutsche Boerse AG)YesCommon SharesDEEURJun 1996
QIAXTRA (XETRA Trading Platform)YesCommon SharesDEEURJun 1996
0RLTLSE (London Stock Exchange)YesCommon SharesGBEURJun 1996
QIADBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURJun 1996
QGENSWX (SIX Swiss Exchange)YesCommon SharesCHCHFJun 1996
QGENWBAG (Wiener Boerse AG)YesCommon SharesATEURJun 1996

Biography

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purifi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/23 22:41
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.